...
首页> 外文期刊>Neurotoxicology >S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters.
【24h】

S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters.

机译:S-腺苷同型半胱氨酸通过增加β-淀粉样蛋白前体蛋白和早老素1的表达以及这些基因启动子的低甲基化,增加BV-2小胶质细胞中β-淀粉样蛋白的形成。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

S-Adenosylhomocysteine (SAH) has been implicated as a risk factor for neurodegenerative diseases such as Alzheimer's disease. As SAH is a potent inhibitor of all cellular methyltransferases, we herein examined the hypothesis that SAH may increase the formation of amyloid beta-peptide (Abeta) in BV-2 mouse microglial cells through hypomethylation of presenilin 1 protein (PS1) and beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), both of which cleave Abeta precursor protein (APP) to form Abeta. The results showed that SAH increased Abeta protein formation in a concentration-dependent manner (10-500 nM), and this effect of SAH was accompanied by significantly increased expression of APP and PS1 proteins, although SAH only significantly increased the expression of BACE1 at the highest concentration used (500 nM). SAH (500 nM) markedly induced hypomethylation of APP and PS1 gene promoters. Incubation of cells with 5'-azc (20 microM), also an inhibitor of DNA methyltransferases enhanced Abeta protein expression and APP and PS1 gene promoters hypomethylation. By contrast, pre-incubation of cells with betaine (1.0 mM), 30 min followed by incubation with SAH (500 nM) or 5'-azc (20 microM) for 24h markedly prevented the expression of Abeta protein (by 50%, P<0.05) and the gene promoter hypomethylation of APP and PS1. Taken together, this study demonstrates that SAH increases the production of Abeta in BV-2 cells possibly by increased expression of APP and induction of hypomethylation of APP and PS1 gene promoters.
机译:S-腺苷同型半胱氨酸(SAH)已被认为是神经退行性疾病(如阿尔茨海默氏病)的危险因素。由于SAH是所有细胞甲基转移酶的有效抑制剂,因此我们在本文中检验了SAH可能通过早老素1蛋白(PS1)和β位的低甲基化增加BV-2小鼠小神经胶质细胞中淀粉样β肽(Abeta)形成的假设。淀粉样蛋白前体蛋白裂解酶1(BACE1),两者均裂解Abeta前体蛋白(APP)形成Abeta。结果显示SAH以浓度依赖性方式(10-500 nM)增加Abeta蛋白的形成,并且SAH的这种作用伴随APP和PS1蛋白的表达显着增加,尽管SAH仅显着增加了BACE1的表达。使用的最高浓度(500 nM)。 SAH(500 nM)明显诱导APP和PS1基因启动子的低甲基化。用5'-azc(20 microM)(也是DNA甲基转移酶的抑制剂)孵育细胞可增强Abeta蛋白表达以及APP和PS1基因启动子的低甲基化。相比之下,将细胞与甜菜碱(1.0 mM)预温育30分钟,然后与SAH(500 nM)或5'-azc(20 microM)温育24h可显着阻止Abeta蛋白的表达(50%,P <0.05)和APP和PS1的基因启动子低甲基化。两者合计,这项研究表明SAH可能通过增加APP的表达以及诱导APP和PS1基因启动子的低甲基化来增加BV-2细胞中Abeta的产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号